BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389. [PMID: 21193998 DOI: 10.1007/s00432-010-0965-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Guo Y, Ziesch A, Hocke S, Kampmann E, Ochs S, De Toni EN, Göke B, Gallmeier E. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis. J Cell Mol Med 2015;19:340-50. [PMID: 25331547 DOI: 10.1111/jcmm.12444] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607-620. [PMID: 23856888 DOI: 10.1038/nrgastro.2013.120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 17.9] [Reference Citation Analysis]
3 Bünger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T. A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer. 2012;12:393. [PMID: 22954206 DOI: 10.1186/1471-2407-12-393] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
4 Gerdtsson AS, Wingren C, Persson H, Delfani P, Nordström M, Ren H, Wen X, Ringdahl U, Borrebaeck CA, Hao J. Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. Mol Oncol 2016;10:1305-16. [PMID: 27522951 DOI: 10.1016/j.molonc.2016.07.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
5 Zhang SY, Zhang SQ, Nagaraju GP, El-rayes BF. Biomarkers for personalized medicine in GI cancers. Molecular Aspects of Medicine 2015;45:14-27. [DOI: 10.1016/j.mam.2015.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Xue A, Chang JW, Chung L, Samra J, Hugh T, Gill A, Butturini G, Baxter RC, Smith RC. Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. Br J Cancer. 2012;107:1883-1891. [PMID: 23169340 DOI: 10.1038/bjc.2012.458] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
7 Chen J, Xu H, Zhu XX. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer. Ther Clin Risk Manag 2016;12:11-8. [PMID: 26730197 DOI: 10.2147/TCRM.S96869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
8 纪道林, 李春龙, 崔云甫. 胰腺癌早期诊断的研究进展. 世界华人消化杂志 2014; 22(17): 2406-2413 [DOI: 10.11569/wcjd.v22.i17.2406] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, Park JY. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54:643-649. [PMID: 23549809 DOI: 10.3349/ymj.2013.54.3.643] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
10 Cheah MT, Chen JY, Sahoo D, Contreras-Trujillo H, Volkmer AK, Scheeren FA, Volkmer JP, Weissman IL. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A 2015;112:4725-30. [PMID: 25825750 DOI: 10.1073/pnas.1424795112] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
11 Conrad C, Fernández-Del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J Surg Oncol. 2013;107:23-32. [PMID: 22674403 DOI: 10.1002/jso.23165] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gui JC, Yan WL, Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med. 2014;14:225-233. [PMID: 23456571 DOI: 10.1007/s10238-013-0234-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
13 Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, Anderson MA, Shedden KA, Ruffin MT, Lubman DM. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res. 2014;13:1873-1884. [PMID: 24571389 DOI: 10.1021/pr400967x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 12.0] [Reference Citation Analysis]
14 Pini M, Rhodes DH, Castellanos KJ, Hall AR, Cabay RJ, Chennuri R, Grady EF, Fantuzzi G. Role of IL-6 in the resolution of pancreatitis in obese mice. J Leukoc Biol. 2012;91:957-966. [PMID: 22427681 DOI: 10.1189/jlb.1211627] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
15 Moutinho-ribeiro P, Coelho R, Giovannini M, Macedo G. Pancreatic cancer screening: Still a delusion? Pancreatology 2017;17:754-65. [DOI: 10.1016/j.pan.2017.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34:3279-3292. [PMID: 23949878 DOI: 10.1007/s13277-013-1033-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
17 Zhang X, Shi X, Lu X, Li Y, Zhan C, Akhtar ML, Yang L, Bai Y, Zhao J, Wang Y, Yao Y, Li Y, Nie H. Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples. J Cancer 2020;11:4641-51. [PMID: 32626510 DOI: 10.7150/jca.41250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liu SH, Hong Y, Markowiak S, Sanchez R, Creeden J, Nemunaitis J, Kalinoski A, Willey J, Erhardt P, Lee J, van Dam M, Brunicardi FC. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Lett 2019;457:10-9. [PMID: 31059751 DOI: 10.1016/j.canlet.2019.04.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Goonesekere NC, Wang X, Ludwig L, Guda C. A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 2014;9:e93046. [PMID: 24740004 DOI: 10.1371/journal.pone.0093046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
20 Rajamani D, Bhasin MK. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis. Genome Med 2016;8:38. [PMID: 27137215 DOI: 10.1186/s13073-016-0282-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
21 Qian L, Li Q, Baryeh K, Qiu W, Li K, Zhang J, Yu Q, Xu D, Liu W, Brand RE, Zhang X, Chen W, Liu G. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res 2019;213:67-89. [PMID: 31442419 DOI: 10.1016/j.trsl.2019.08.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 14.5] [Reference Citation Analysis]
22 Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE, Tollenaar RA, Vasen HF. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Transl Oncol 2016;9:242-7. [PMID: 27267843 DOI: 10.1016/j.tranon.2016.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
23 Le N, Sund M, Vinci A; GEMS collaborating group of Pancreas 2000. Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis 2016;48:223-30. [PMID: 26769569 DOI: 10.1016/j.dld.2015.11.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 11.3] [Reference Citation Analysis]
24 Függer R, Gangl O, Fröschl U. Clinical approach to the patient with a solid pancreatic mass. Wien Med Wochenschr 2014;164:73-9. [PMID: 24577681 DOI: 10.1007/s10354-014-0266-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Pang Y, Holmes MV, Chen Z, Kartsonaki C. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2019;34:330-45. [PMID: 30550622 DOI: 10.1111/jgh.14576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
26 Chen H, Li F, Zou S, Xie J, Zhang J, Deng X, Chen H, Shen B. Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection. World J Surg Oncol 2021;19:166. [PMID: 34107980 DOI: 10.1186/s12957-021-02281-8] [Reference Citation Analysis]
27 Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2013;139:1117-1127. [PMID: 23546595 DOI: 10.1007/s00432-013-1422-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
28 Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumour Biol. 2015;36:1375-1384. [PMID: 25680410 DOI: 10.1007/s13277-015-3223-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
29 Root A, Allen P, Tempst P, Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel) 2018;10:E67. [PMID: 29518918 DOI: 10.3390/cancers10030067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
30 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Reference Citation Analysis]
31 Baine MJ, Menning M, Smith LM, Mallya K, Kaur S, Rachagani S, Chakraborty S, Sasson AR, Brand RE, Batra SK. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Cancer Biomark 2011-2012;11:1-14. [PMID: 22820136 DOI: 10.3233/CBM-2012-0260] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
32 Fang Y, Yao Q, Chen Z, Xiang J, William FE, Gibbs RA, Chen C. Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit. 2013;19:916-926. [PMID: 24172537 DOI: 10.12659/msm.889636] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
33 Passerini R, Cassatella MC, Boveri S, Salvatici M, Radice D, Zorzino L, Galli C, Sandri MT. The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 2012;138:281-7. [PMID: 22904141 DOI: 10.1309/AJCPOPNPLLCYR07H] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
34 England CG, Hernandez R, Eddine SB, Cai W. Molecular Imaging of Pancreatic Cancer with Antibodies. Mol Pharm 2016;13:8-24. [PMID: 26620581 DOI: 10.1021/acs.molpharmaceut.5b00626] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
35 Bünger S, Zimmermann M, Habermann JK. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials. Cancer Metastasis Rev 2015;34:527-45. [PMID: 26323491 DOI: 10.1007/s10555-015-9582-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
36 Suh HN, Jun S, Oh AY, Srivastava M, Lee S, Taniguchi CM, Zhang S, Lee WS, Chen J, Park BJ, Park JI. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Sci Rep 2016;6:38273. [PMID: 27922049 DOI: 10.1038/srep38273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
37 Crawley AS, O'Kennedy RJ. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Rev Mol Diagn 2015;15:1339-53. [PMID: 26394703 DOI: 10.1586/14737159.2015.1083862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
38 Danielsson K, Ansari D, Andersson R. Personalizing pancreatic cancer medicine: what are the challenges? Personalized Medicine 2013;10:45-59. [DOI: 10.2217/pme.12.111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
40 Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, Saad A, ChinAleong J, Hurt C, Cox C, Salvia R, Mantovani A, Crnogorac-Jurcevic T, Mukherjee S, Scarpa A, Allavena P, Kocher HM. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol 2021;5:61. [PMID: 34188166 DOI: 10.1038/s41698-021-00192-1] [Reference Citation Analysis]
41 Kim H, Youk J, Yang Y, Kim TY, Min A, Ham HS, Cho S, Lee KH, Keam B, Han SW, Oh DY, Ryu HS, Han W, Park IA, Kim TY, Noh DY, Im SA. Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. J Cancer Res Clin Oncol 2016;142:707-14. [PMID: 26577828 DOI: 10.1007/s00432-015-2072-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
42 Nie S, Yin H, Tan Z, Anderson MA, Ruffin MT, Simeone DM, Lubman DM. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method. J Proteome Res 2014;13:6058-66. [PMID: 25393578 DOI: 10.1021/pr500934u] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
43 Hu H, Zhang Q, Huang C, Shen Y, Chen X, Shi X, Tang W. Diagnostic value of S100P for pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:9479-9485. [PMID: 25123266 DOI: 10.1007/s13277-014-2461-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
44 Haeri HH, Tomaszewski J, Phytides B, Schimm H, Möslein G, Niedergethmann M, Hinderberger D, Gelos M. Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. ACS Pharmacol Transl Sci 2020;3:1188-98. [PMID: 33344896 DOI: 10.1021/acsptsci.0c00116] [Reference Citation Analysis]
45 Gerdtsson AS, Malats N, Säll A, Real FX, Porta M, Skoog P, Persson H, Wingren C, Borrebaeck CA. A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Int J Proteomics 2015;2015:587250. [PMID: 26587286 DOI: 10.1155/2015/587250] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
46 Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol 2021; 27(23): 3158-3181 [PMID: 34163104 DOI: 10.3748/wjg.v27.i23.3158] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tobi M, Kim M, Weinstein DH, Rambus MA, Hatfield J, Adsay NV, Levi E, Evans D, Lawson MJ, Fligiel S. Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma. Dig Dis Sci. 2013;58:744-750. [PMID: 23001406 DOI: 10.1007/s10620-012-2387-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
48 张建忠, 谢生智, 陈海英. 血清糖链抗原242诊断胰腺癌价值的系统评价. 世界华人消化杂志 2015; 23(14): 2310-2317 [DOI: 10.11569/wcjd.v23.i14.2310] [Reference Citation Analysis]
49 van Noort JM, Bsibsi M, Nacken P, Gerritsen WH, Amor S. The link between small heat shock proteins and the immune system. Int J Biochem Cell Biol 2012;44:1670-9. [PMID: 22233974 DOI: 10.1016/j.biocel.2011.12.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
50 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
51 Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013;11:1067-1072. [PMID: 24161419 DOI: 10.1016/j.ijsu.2013.10.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
52 Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q, Yu X. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 2013;17:2092-2098. [PMID: 24146342 DOI: 10.1007/s11605-013-2389-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
53 Dimastromatteo J, Brentnall T, Kelly KA. Imaging in pancreatic disease. Nat Rev Gastroenterol Hepatol 2017;14:97-109. [DOI: 10.1038/nrgastro.2016.144] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
54 Kashyap S, Pal S, Chandan G, Saini V, Chakrabarti S, Saini NK, Mittal A, Thakur VK, Saini AK, Saini RV. Understanding the cross-talk between human microbiota and gastrointestinal cancer for developing potential diagnostic and prognostic biomarkers. Semin Cancer Biol 2021:S1044-579X(21)00121-8. [PMID: 33971261 DOI: 10.1016/j.semcancer.2021.04.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Shi J, Lew M, Zalupski MM, Roh MH, Kwon RS, Pang JC. Implication of Suspicious Cytology in Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Pancreatic Cancer. J Gastrointest Canc 2015;46:54-9. [DOI: 10.1007/s12029-014-9681-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012;18:2439-51. [PMID: 22372502 DOI: 10.2174/13816128112092439] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
57 Herreros-Villanueva M, Gironella M, Castells A, Bujanda L. Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta. 2013;418:22-29. [PMID: 23305796 DOI: 10.1016/j.cca.2012.12.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
58 Kaleağasıoğlu F, Berger MR. SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14747-14759 [PMID: 25356037 DOI: 10.3748/wjg.v20.i40.14747] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
59 Beck JG, Skuratovsky A, Granger MC, Porter MD. Calibrant-Free Analyte Quantitation via a Variable Velocity Flow Cell. Anal Chem 2017;89:1147-54. [PMID: 27935676 DOI: 10.1021/acs.analchem.6b03527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
60 Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J, Zhang J. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol 2020;18:31. [PMID: 32028958 DOI: 10.1186/s12957-020-1809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Meng Q, Shi S, Liang C, Xiang J, Liang D, Zhang B, Qin Y, Ji S, Xu W, Xu J, Ni Q, Yu X. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2017;8:3615-3622. [PMID: 29151947 DOI: 10.7150/jca.18901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
62 Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:174-82. [PMID: 30333219 DOI: 10.1158/1055-9965.EPI-18-0483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
63 Kosanam H, Makawita S, Judd B, Newman A, Diamandis EP. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics 2011;11:4551-8. [PMID: 21932441 DOI: 10.1002/pmic.201100264] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
64 Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014; 20(31): 10802-10812 [PMID: 25152583 DOI: 10.3748/wjg.v20.i31.10802] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
65 Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41:143-157. [PMID: 22341255 DOI: 10.1016/j.gtc.2011.12.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
66 Marengo E, Robotti E. Biomarkers for pancreatic cancer: Recent achievements in proteomics and genomics through classical and multivariate statistical methods. World J Gastroenterol 2014; 20(37): 13325-13342 [PMID: 25309068 DOI: 10.3748/wjg.v20.i37.13325] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
67 Moutinho-Ribeiro P, Macedo G, Melo SA. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol (Lausanne) 2018;9:779. [PMID: 30671023 DOI: 10.3389/fendo.2018.00779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
68 Xu H, Zhu XX, Chen J. DNT cell inhibits the growth of pancreatic carcinoma via abnormal expressions of NKG2D and MICA in vivo. Biochem Biophys Res Commun 2016;469:145-50. [PMID: 26616050 DOI: 10.1016/j.bbrc.2015.11.085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Zhou YF, Xu LX, Huang LY, Guo F, Zhang F, He XY, Yuan YZ, Yao WY. Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer. Oncol Lett. 2014;8:2096-2102. [PMID: 25295097 DOI: 10.3892/ol.2014.2429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
70 Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34. [PMID: 23026552 DOI: 10.1016/j.jprot.2012.09.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
71 Park JY, Hiroshima Y, Lee JY, Maawy AA, Hoffman RM, Bouvet M. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. PLoS One 2015;10:e0122100. [PMID: 25815753 DOI: 10.1371/journal.pone.0122100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
72 Padoan A, Seraglia R, Basso D, Fogar P, Sperti C, Moz S, Greco E, Marchet A, de Manzoni G, Zambon C, Navaglia F, Cristadoro L, Di Chiara A, Nitti D, Pedrazzoli S, Pavanello G, Plebani M. Usefulness of MALDI-TOF/MS Identification of Low-MW Fragments in Sera for the Differential Diagnosis of Pancreatic Cancer. Pancreas 2013;42:622-32. [DOI: 10.1097/mpa.0b013e318273096c] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, Krishn SR, Mallya K, Aithal A, Sasson AR, Johansson SL, Jain M, Singh S, Guha S, Are C, Raimondo M, Hollingsworth MA, Brand RE, Batra SK. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am J Gastroenterol. 2017;112:172-183. [PMID: 27845339 DOI: 10.1038/ajg.2016.482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]